Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.66 USD
-0.09 (-3.27%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Esperion Therapeutics, Inc. has a PEG ratio of 0.84 compared to the Medical - Drugs industry's PEG ratio of 1.36.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ESPR 2.66 -0.09(-3.27%)
Will ESPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock?
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Other News for ESPR
ESPR's price falls by 3.27% on September 20, though its technical setup remains stable.
Esperion’s Strategic Milestone: Nexletol Approval in Japan Boosts Financial Outlook with $120 Million Potential
ESPR: HC Wainwright & Co. Reiterates Buy Rating with $16 Target | ESPR Stock News
Esperion’s Strategic Advancements: Regulatory Approval and Market Expansion Boost
NEXLETOL Approval in Japan Boosts Esperion (ESPR) Prospects